Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the ...

Finding offers potential new target for treatmentPsoriasis, a painful and uncomfortable inflammatory skin condition that ...

Board-certified dermatologist with New York City-based MDCS Dermatology Dr. Brendan ... that salicylic acid is a beta hydroxy ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

A new study published in the Archives of Dermatological Research found that patients with psoriasis who were receiving ...

CLEVELAND—Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...

People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased propensity for 'leaky gut', according to new research. These changes in the gut ...

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...